Trials / Completed
CompletedNCT03580668
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA \<50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B/F/TAF | B/F/TAF administered in accordance with the approved product monograph |
Timeline
- Start date
- 2018-11-13
- Primary completion
- 2024-06-03
- Completion
- 2024-06-03
- First posted
- 2018-07-09
- Last updated
- 2024-06-18
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03580668. Inclusion in this directory is not an endorsement.